Basiliximab, previously known as CHI 621 and possessing the chemical identifier 179045-86-4, represents a antibody agent utilized primarily in suppressing acute repudiation following organ transplantation . This engineered protein specifically interacts with the interleukin-2 (IL-2) site, effectively hindering IL-2 signaling and subsequently Basili